Core Points - Three companies, Zhongxin Co., Ltd. (603091.SH), Hehe Information (688615.SH), and Innos (688710.SH), will start trading under the "Shanghai-Hong Kong Stock Connect" from October 27, 2025 [1] - These companies will be included as eligible securities in the Central Clearing System, with trading conducted in Renminbi [1] - The Hong Kong Clearing will not provide physical stock custody and withdrawal services for these securities [1] Summary by Category Company Information - Zhongxin Co., Ltd. (603091) will be trading under the English name "ZHEJIANG ZHON-A" [2] - Hehe Information (688615) will be trading under the English name "INTSIG INFORM-A" [2] - Innos (688710) will be trading under the English name "SHANGHAI INNO-A" [2] Trading Mechanism - The trading of these companies will follow the general rules and operational procedures of Hong Kong Clearing [1] - The settlement and clearing will be conducted under the continuous net settlement system of the Central Clearing System [1]

Core Insights - Yinosh experienced a decline of 1.41% on October 16, with a trading volume of 56.32 million yuan [1] - The company reported a financing net buy of -1.44 million yuan on the same day, indicating a higher level of financing repayment compared to new purchases [1] - As of October 16, the total financing and securities lending balance for Yinosh was 73.64 million yuan, which is 1.93% of its circulating market value, indicating a low financing level compared to the past year [1] Financial Performance - For the first half of 2025, Yinosh achieved an operating income of 375 million yuan, a year-on-year decrease of 38.04% [2] - The net profit attributable to the parent company was -15.19 million yuan, reflecting a significant year-on-year decline of 115.88% [2] Shareholder and Institutional Holdings - As of June 30, 2025, the number of Yinosh shareholders was 5,386, a decrease of 0.90% from the previous period [2] - The top ten circulating shareholders included new entrants such as ICBC Strategic Transformation Stock A and Harvest Medical Health Stock A, while some previous shareholders exited the top ten list [3]

Core Insights - The medical services sector experienced a significant increase of 2.96% on October 15, with Boteng Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3912.21, up 1.22%, while the Shenzhen Component Index closed at 13118.75, up 1.73% [1] Medical Services Sector Performance - Boteng Co., Ltd. (300363) closed at 24.80, with a rise of 6.85% and a trading volume of 317,100 shares, amounting to a transaction value of 772 million [1] - MediX (688202) saw a closing price of 62.49, up 6.28%, with a trading volume of 53,300 shares, totaling 328 million [1] - Haoyuan Pharmaceutical (688131) closed at 77.20, increasing by 6.19%, with a trading volume of 50,200 shares, resulting in a transaction value of 379 million [1] - Other notable performers included Jiuzhou Pharmaceutical (603456) with a 6.04% increase, and Ruizhi Pharmaceutical (300149) with a 5.97% increase [1] Capital Flow Analysis - The medical services sector saw a net inflow of 448 million from institutional investors, while retail investors experienced a net outflow of 118 million [2] - The top stocks by net inflow from institutional investors included Innovation Medical (002173) with 92.95 million and Meinian Health (002044) with 88.56 million [3] - Conversely, retail investors showed significant outflows from Meinian Health (002044) at 93.20 million and Aier Eye Hospital (300015) at 5.37 million [3]

Core Viewpoint - Yinosh experienced a decline of 3.52% on October 13, with a trading volume of 58.50 million yuan, indicating a challenging market environment for the company [1] Financing Summary - On October 13, Yinosh had a financing buy-in amount of 6.76 million yuan and a financing repayment of 5.42 million yuan, resulting in a net financing buy of 1.34 million yuan [1] - As of October 13, the total financing and securities lending balance for Yinosh was 70.05 million yuan, which accounts for 1.78% of its market capitalization, indicating a low financing balance compared to the past year [1] - The company had no securities lending activity on October 13, with a securities lending balance of 0.00 shares, placing it at a high level compared to the past year [1] Company Overview - Shanghai Yinosh Biotechnology Co., Ltd. was established on May 12, 2010, and is located in the China (Shanghai) Pilot Free Trade Zone [1] - The company specializes in providing comprehensive research and development services (CRO) primarily focused on non-clinical research services, with 96.31% of its revenue coming from non-clinical services [1] Financial Performance - For the period from January to June 2025, Yinosh reported an operating income of 375 million yuan, a year-on-year decrease of 38.04%, and a net profit attributable to shareholders of -15.19 million yuan, reflecting a significant decline of 115.88% year-on-year [2] Shareholder Information - As of June 30, 2025, Yinosh had 5,386 shareholders, a decrease of 0.90% from the previous period, with an average of 5,235 circulating shares per person, which is an increase of 0.91% [2] - The company has distributed a total of 45.11 million yuan in dividends since its A-share listing [3] - Notable changes in institutional holdings include ICBC Medical Health Stock becoming the seventh largest shareholder, increasing its holdings by 72,300 shares, while new shareholders include ICBC Strategic Transformation Stock and Harvest Medical Health Stock [3]

Overview - The global CRO market is projected to reach $90.03 billion by 2024, with the preclinical CRO market accounting for $27.46 billion, representing 30.5% of the total CRO market [1][9]. - The increasing prevalence of chronic diseases and heightened health awareness are driving demand for high-quality biopharmaceutical products and related research services [1][9]. Industry Barriers - The preclinical CRO sector faces significant entry barriers due to the need for experienced professionals and established operational expertise, which new entrants may struggle to acquire quickly [5][6]. - Established CROs typically have over 10 years of experience, making it challenging for newcomers to compete effectively [5]. Market Policies - The pharmaceutical manufacturing industry is a key focus for development in China, supported by various policies aimed at encouraging new drug research and optimizing approval processes [7]. - Recent policies include guidelines for improving drug quality and promoting digital healthcare, creating a favorable environment for the preclinical CRO industry [7]. Industry Chain - The upstream of the preclinical CRO industry includes suppliers of experimental materials, laboratory animals, scientific instruments, and data analysis software [8]. - The primary clients for preclinical CROs are pharmaceutical companies, which outsource research to reduce costs and improve efficiency [8]. Development Status - China's CRO market is expected to reach 89.22 billion yuan in 2024, with a year-on-year growth of 5.19%, and the preclinical CRO market is projected to reach 42.91 billion yuan, growing by 5.74% [9]. - The demand for CRO services is expanding due to the aging population and rising chronic disease rates in China [9]. Competitive Landscape - The global preclinical CRO market is dominated by established companies in the US and Western Europe, with the US holding a significant market share [10][11]. - Domestic companies like WuXi AppTec and Kanglong Chemical are gaining competitive advantages by understanding local regulations and market needs, offering tailored services at lower costs [11]. Representative Domestic Companies - WuXi AppTec reported a total revenue of 39.24 billion yuan in 2024, with a gross profit of 16.02 billion yuan and a gross margin of 40.8% [12]. - YinuoSi achieved a total revenue of 1.142 billion yuan in 2024, with 95.4% of this revenue coming from its non-clinical CRO services [12][13]. Development Trends - Future advancements in AI and big data analytics are expected to enhance drug discovery and toxicology assessments, improving efficiency and accuracy in the preclinical CRO sector [13]. - There will be a growing emphasis on personalized solutions targeting specific diseases or patient groups, necessitating diverse disease models for drug development [13].

Core Insights - Yinos's stock price dropped by 4.30% on September 26, with a trading volume of 68.4983 million yuan [1] - The company reported a financing net buy of -1.9928 million yuan on the same day, indicating more repayments than new purchases [1] - As of September 26, the total margin balance for Yinos was 73.0346 million yuan, which is 1.70% of its market capitalization, reflecting a low financing level compared to the past year [1] Financial Performance - For the first half of 2025, Yinos achieved operating revenue of 375 million yuan, a year-on-year decrease of 38.04% [2] - The net profit attributable to the parent company was -15.1895 million yuan, a significant decline of 115.88% compared to the previous period [2] Shareholder and Institutional Holdings - As of June 30, 2025, the number of Yinos shareholders was 5,386, a decrease of 0.90% from the previous period [2] - The top ten circulating shareholders include ICBC Medical Health Stock, which increased its holdings by 72,300 shares to 439,400 shares [3] - New institutional shareholders include ICBC Strategic Transformation Stock and Harvest Medical Health Stock, which entered the top ten list [3]

Core Insights - Yinosh's stock increased by 2.46% on September 25, with a trading volume of 107 million yuan [1] - The company reported a financing net purchase of 2.2852 million yuan on the same day, with a total financing balance of 75.0274 million yuan, representing 1.67% of its market capitalization [1] - Yinosh's main business involves providing non-clinical research services in the biopharmaceutical sector, with 96.31% of its revenue coming from non-clinical services [1] Financial Performance - As of June 30, Yinosh's revenue for the first half of 2025 was 375 million yuan, a year-on-year decrease of 38.04% [2] - The company reported a net profit attributable to shareholders of -15.1895 million yuan, a significant decline of 115.88% compared to the previous period [2] Shareholder and Institutional Holdings - As of June 30, the number of Yinosh's shareholders was 5,386, a decrease of 0.90% from the previous period [2] - The top ten circulating shareholders include ICBC Medical Health Stock, which increased its holdings by 72,300 shares, and two new shareholders, namely ICBC Strategic Transformation Stock and Harvest Medical Health Stock [3]

Group 1 - The core viewpoint of the news is that Yinosh Biotechnology Co., Ltd. has seen a stock price increase of 5.11%, reaching 50.80 CNY per share, with a total market capitalization of 7.162 billion CNY as of September 25 [1] - Yinosh specializes in providing non-clinical research services in the biopharmaceutical sector, with 96.31% of its revenue coming from non-clinical services, 3.42% from clinical services, and 0.27% from other sources [1] - The company is located in the China (Shanghai) Pilot Free Trade Zone and was established on May 12, 2010, with its listing date set for September 3, 2024 [1] Group 2 - Among Yinosh's top ten circulating shareholders, a fund under Harvest Fund Management, specifically the Harvest Medical Health Stock A (005303), has entered the top ten, holding 344,300 shares, which is 1.22% of the circulating shares [2] - The Harvest Medical Health Stock A fund has achieved a year-to-date return of 46.46%, ranking 892 out of 4220 in its category, and a one-year return of 60.55%, ranking 1402 out of 3820 [2] - The fund was established on December 4, 2017, and has a current size of 786 million CNY, with an overall return since inception of 99.56% [2] Group 3 - The fund manager of Harvest Medical Health Stock A is Sun Xiaohui, who has been in the position for 168 days, achieving a best return of 39.35% during his tenure [3] - The other fund manager, Hao Miao, has been managing the fund for 6 years and 254 days, with a best return of 183.83% and a worst return of -29.32% during his tenure [3]

Group 1 - The core point of the announcement is the resolution of the third extraordinary general meeting of shareholders held by Shanghai Yinos Biotech Co., Ltd., confirming that there were no rejected proposals [1] - The meeting was conducted in compliance with the Company Law and the company's articles of association, with a combination of on-site and online voting methods [2] - All current directors and supervisors attended the meeting, ensuring full representation of the board [3] Group 2 - Two key proposals were approved during the meeting: the reappointment of the accounting firm and the purchase of directors and officers liability insurance [4] - The meeting was held on September 23, 2025, at the designated location in Shanghai [4] - The voting results indicated that all proposals received more than half of the valid voting rights from attending shareholders, with separate counting for minority investors [5] Group 3 - The meeting was witnessed by lawyers from Guohao Law Firm, confirming that the procedures and voting methods adhered to legal requirements [5]

2025 年第三次临时股东大会的 法律意见书 致：上海益诺思生物技术股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》（以下简称"《证券法》"）和中国证券监督管理委员会《上市公司股东 会规则》（以下简称"《股东会规则》"）的规定，国浩律师（上海）事务所接受上 海益诺思生物技术股份有限公司（以下简称"公司"）董事会的聘请，指派律师出席 并见证了公司于 2025 年 9 月 23 日召开的公司 2025 年第三次临时股东大会现场会 议，并依据有关法律、法规、规范性文件的规定以及《上海益诺思生物技术股份 有限公司章程》（以下简称"《公司章程》"）的规定，对本次股东大会的召集、召 开程序、出席人员资格、大会表决程序和表决结果等事宜进行了审查，现发表法 律意见如下： 北京 上海 深圳 杭州 广州 昆明 天津 成都 宁波 福州 西安 南京 南宁 济南 香港 巴黎 马德里 硅谷 BEIJING SHANGHAI SHENZHEN HANGZHOU GUANGZHOU KUNMING TIANJIN CHENGDU NINGBO FUZHOU XI'AN NANJING NANN ...